{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}],"title":"Non-serious AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.","groups":[{"description":"Participants received Niraparib 300 mg in fasted condition","id":"OG000","title":"FE Niraparib Fasted"},{"description":"Participants received Niraparib 300 mg in fed condition","id":"OG001","title":"FE Niraparib Fed"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Up to 2 years, 3 months and 11 days","title":"Number of Participants With Non-serious AEs and SAEs in FE Sub-study","type":"SECONDARY","unitOfMeasure":"Participants"}